Showing results 1 to 20 of 27
next >
| Preview | Issue Date | Title / Name | Author(s) |
| Jul-2007 | Cancer services to be proud of in rural Australia: lessons learnt from the Clinical Oncological Society of Australia cancer service audit | Begbie, S.; Underhill, C.; Begbie, Stephen | |
| May-2009 | A couple with gastrointestinal stromal tumor (GIST) | Poursoltan, P.; Begbie, S.; Poursoltan, Pirooz; Begbie, Stephen | |
| Dec-2013 | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; Efstathiou, E.; Oudard, S.; Morris, M. J.; Goebell, P. J.; Heidenreich, A.; de Bono, J. S.; Begbie, S.; et. al; Begbie, Stephen | |
| Jun-2016 | Effects of a Structured Exercise Program on Physical Activity and Fitness in Colon Cancer Survivors: One Year Feasibility Results from the CHALLENGE Trial | Courneya, K. S.; Vardy, J. L.; O'Callaghan, C. J.; Friedenreich, C. M.; Campbell, K. L.; Prappavessis, H.; Crawford, J. J.; O'Brien, P.; Dhillon, H. M.; Jonker, D. J.; Chua, N. S.; Lupichuk, S.; Sanatani, M. S.; Gill, S.; Meyer, R. M.; Begbie, S.; Bonaventura, T.; Burge, M. E.; Turner, J.; Tu, D.; Booth, C. M.; Begbie, Stephen | |
| Mar-2018 | Elective hepatic resection is feasible and safe in a regional centre | Gray, A.D.; Petrou, G.; Rastogi, P.; Begbie, Stephen; Gray, A.D.; Petrou, G.; Rastogi, P.; Begbie, Stephen | |
| Jul-2019 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer | Davis, I. D.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenbuerg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S, G,; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; Begbie, Stephen | |
| Mar-2022 | Health-related quality of life in metastatic hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international randomized phase III trial led by ANZUP | Stockler, M. R.; Martin, A. J.; Davis, I. D.; Dhillon, H. M.; Begbie, S. D.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W. R.; Pook, D. W.; Reaume, M. N.; Sandhu, S.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; ENSAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen | |
| Aug-1995 | Hypofractionated irradiation for inoperable non-small cell lung cancer | Stevens, M. J.; Begbie, S. D.; Begbie, Stephen | |
| 1996 | Is measurement of total body nitrogen (TBN) a useful predictor of chemotherapy (C/T) toxicity in breast cancer? | Aslani, A.; Begbie, S.; Smith, R. C.; Alle, B. J.; Begbie, Stephen | |
| Feb-1996 | A late complication of palliative stenting of malignant oesophageal obstruction | Begbie, S.; Briggs, G.; Levi, J.; Begbie, Stephen | |
| Oct-2009 | Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study | Ciuleanu, T.; Brodowicz, T.; Zielinski, C.; Kim, J. H.; Krzakowski, M.; Laack, E.; Wu, T-L; Bover, I.; Begbie, S.; Tzekova, V.; Cucevic, B.; Pereira, J. R.; Yang, S. H.; Madhavan, J.; Sugarman, K. P.; Peterson, P.; John, W. J.; Krejcy, K.; Belani, C. P.; Begbie, Stephen | |
| Jan-1993 | Maloprim-induced pulmonary eosinophilia | Begbie, S.; Burgess, K. R.; Begbie, Stephen | |
| Dec-2009 | Mapping oncology services in regional and rural Australia | Underhill, C.; Bartel, R.; Goldstein, D.; Snodgrass, H.; Begbie, S.; Yates, P.; White, K.; Jong, K.; Grogan, P.; Begbie, Stephen | |
| Sep-2014 | Multidisciplinary consensus: a practical guide for the integration of abiraterone into clinical practice | Woo, H. H.; Begbie, S.; Gogna, K.; Mainwaring, P. N.; Murphy, D. G.; Parnis, F.; Steer, C.; Davis, I. E.; Begbie, Stephen | |
| Sep-2023 | NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma | Sim, H. W.; Wachsmuth, L.; Barnes, E. H.; Yip, S.; Koh, E. S.; Hall, M.; Jennens, R.; Ashley, D. M.; Verhaak, R. G.; Heimberger, A. B.; Rosenthal, M. A.; Hovey, E. J.; Ellingson, B. M.; Tognela, A.; Gan, H. K.; Wheeler, H.; Back, M.; McDonald, K. L.; Long, A.; Cuff, K.; Begbie, S.; Gedye, C.; Mislang, A.; Le, Hien; Johnson, M. O.; Kong, B. Y.; Simes, J. R.; Lwin, Z.; Khasraw, M.; Begbie, Stephen | |
| Dec-2024 | Oral Cannabis Extract for Secondary Prevention of Chemotherapy-Induced Nausea and Vomiting - Final Results of a Randomized, Placebo-Controlled, Phase II/III Trial | Grimison, P.; Mersiades, A.; Kirby, A.; Morton, R.L.; Walsh, A.; Lee, Y.; Simes, R.J.; Stockler, M.R.; Tognela, A.; Olver, I.; Haber, P.; Abdi, E.; Della-Fiorentina, S.; Aghmesheh, M.; Fox, P.; Briscoe, Karen; Sanmugarajah, J.; Marx, G.; Kichenadasse, G.; Wheeler, H.; Chan, M.; Shannon, J.; Gedye, C.; Begbie, Stephen; Briscoe, Karen; Begbie, Stephen | |
| Dec-2003 | Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial | Scheithauer, W.; McKendrick, J.; Begbie, S.; Borner, M.; Burns, W. I.; Burris, H. A.; Cassidy, J.; Jodrell, D.; Koralewski, P.; Levine, E. L.; Marschner, N.; Maroun, J.; Garcia-Alfonso, P.; Tujakowski, J.; Van Hazel, G.; Wong, A.; Zaluski, J.; Twelves, C.; Begbie, Stephen | |
| Nov-2020 | Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial. | Grimison, P.; Mersiades, A.; Kirby, A.; Lintzeris, N.; Morton, R.; Haber, P.; Olver, I.; Walsh, A.; McGregor, I.; Cheung, Y.; Tognela, A.; Hahn, C.; Briscoe, Karen; Aghmesheh, M.; Fox, P.; Abdi, E.; Clarke, S.; Della-Fiorentina, S.; Shannon, J.; Gedye, C.; Begbie, Stephen; Simes, J.; Stockler, M.; Briscoe, Karen; Begbie, Stephen | |
| Sep-2021 | Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Begbie, Stephen | |
| Aug-2023 | Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial | Antonarakis, E.; Park, S. H.; Goh, J. C.; Shin, S. J.; Lee, J. L.; Mehra, N.; Dermott, R.; Sala-Gonzalez, N.; Fong, P. C.; Greil, R.; Retz, M.; Sade, J. P.; Yanez, P.; Huang, Y.; Begbie, S. D.; et. al; Begbie, Stephen | |
